Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

See my last post. I think the only issue doc williams made was choosing the primary endpoint they did. I mean, they even came out and said after the release, "we didn't really expect to find a change here for this endpoint"... well.. that is inherently an issue.

I think whoever did the data analysis (e.g. australian contractors?) have increased the sample on the interim analysis and thats problematic. You cant change your plan like that unless your trying to hide something.

They deserve credit for giving this a shot, no doubt. But don't manipulate the plan. It is indeed shady behaviour. They have shown us the almost full data but did so by increasing the sample to find signal.

If this type of change of the plan occurs in real scientific studies, they are disregarded and don't get published, or they have to state it as a limitation because of the potential for post hoc data manipulation.